Interpace Biosciences General and Administrative Expenses 2011-2026 | IDXG

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Interpace Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
9.49 M	9.36 M	11 M	10.7 M	20.8 M	14.5 M	8.5 M	9.15 M	10.5 M	16.9 M	29.2 M	28.7 M	27.9 M	34.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
34.3 M	8.5 M	17.2 M

Quarterly General and Administrative Expenses Interpace Biosciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
2.06 M	2.66 M	2.55 M	-	2.54 M	2.14 M	2.24 M	-	2.12 M	2.89 M	2.49 M	-	2.77 M	2.98 M	2.89 M	-	2.57 M	3.33 M	2.98 M	-	3.8 M	3.98 M	4.84 M	-	4.49 M	2.79 M	2.74 M	-	2.08 M	1.73 M	2.17 M	-	2.12 M	2.79 M	1.52 M	-	2.86 M	2.02 M	2.82 M	-	2.5 M	3.43 M	3.34 M	-	6.93 M	6.26 M	5.53 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.93 M	1.52 M	3.05 M

General and Administrative Expenses of other stocks in the Diagnostics research industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Akumin AKU	2.08 M	-	-17.87 %	$ 25.9 M	Canada
Centogene N.V. CNTG	46.7 M	-	-6.23 %	$ 30.6 M	Germany
Accelerate Diagnostics AXDX	39.2 M	-	-61.36 %	$ 2.46 M	USA
Brainsway Ltd. BWAY	5.78 M	$ 19.02	0.21 %	$ 99.4 M	Israel
Co-Diagnostics CODX	14.3 M	$ 0.17	-6.7 %	$ 4.99 M	USA
Burning Rock Biotech Limited BNR	490 M	$ 20.15	-2.3 %	$ 217 M	China
Danaher Corporation DHR	7.76 B	$ 228.92	-0.76 %	$ 167 B	USA
Biocept BIOC	16.1 M	-	-13.05 %	$ 7.29 M	USA
Chembio Diagnostics CEMI	24.3 M	-	0.22 %	$ 16.8 M	USA
DexCom DXCM	1.19 B	$ 66.37	-1.03 %	$ 25.6 B	USA
BioNano Genomics BNGO	51.9 M	$ 1.53	2.0 %	$ 1.94 M	USA
Castle Biosciences CSTL	200 M	$ 38.9	-1.04 %	$ 1.08 B	USA
Oxford Immunotec Global PLC OXFD	22.3 M	-	-	$ 562 M	Britain
DermTech DMTK	43.8 M	-	-11.32 %	$ 2.94 M	USA
DarioHealth Corp. DRIO	18.1 M	$ 11.38	6.36 %	$ 323 M	Israel
IQVIA Holdings IQV	1.99 B	$ 225.41	-1.0 %	$ 40.9 B	USA
Enzo Biochem ENZ	21.7 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	191 M	$ 101.56	-0.33 %	$ 18.8 B	USA
Fulgent Genetics FLGT	88.1 M	$ 26.27	-0.83 %	$ 794 M	USA
Global Cord Blood Corporation CO	187 M	-	-	$ 399 M	China
Fluidigm Corporation FLDM	97.9 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	3.83 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	126 M	-	0.12 %	$ 80.1 M	China
PRA Health Sciences, Inc. PRAH	453 M	-	-	$ 10.7 B	USA
Myriad Genetics MYGN	276 M	$ 6.15	-0.32 %	$ 557 M	USA
CareDx, Inc CDNA	118 M	$ 18.84	-1.21 %	$ 1.01 B	USA
NeoGenomics NEO	260 M	$ 11.76	-3.84 %	$ 1.49 B	USA
Celcuity CELC	9.06 M	$ 99.74	-0.18 %	$ 3.93 B	USA
National Research Corporation NRC	46.6 M	$ 18.77	0.64 %	$ 461 M	USA
Anixa Biosciences ANIX	7.44 M	$ 3.12	-	$ 99.5 K	USA
Precipio PRPO	9.45 M	$ 22.98	-1.84 %	$ 29.8 M	USA
Personalis PSNL	46.2 M	$ 7.96	-0.13 %	$ 472 M	USA
Heska Corporation HSKA	64.1 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	15.8 M	-	-20.0 %	$ 1.06 M	USA
Guardant Health GH	180 M	$ 102.14	1.53 %	$ 12.5 B	USA
Aspira Women's Health AWH	16.2 M	-	-6.19 %	$ 10.5 M	USA
ENDRA Life Sciences NDRA	7.06 M	$ 4.53	-4.83 %	$ 2.43 M	USA
Soleno Therapeutics SLNO	106 M	$ 46.3	0.02 %	$ 1.86 B	USA
Illumina ILMN	1.09 B	$ 131.16	-1.2 %	$ 20.9 B	USA
Charles River Laboratories International CRL	751 M	$ 199.48	-1.24 %	$ 10.2 B	USA
Thermo Fisher Scientific TMO	8.6 B	$ 579.45	-0.69 %	$ 221 B	USA
Trinity Biotech plc TRIB	24.7 M	$ 0.79	-3.54 %	$ 61.9 M	Irlanda
Quest Diagnostics Incorporated DGX	1.77 B	$ 173.53	-1.12 %	$ 19.3 B	USA
Biodesix BDSX	80.5 M	$ 6.8	1.19 %	$ 882 M	USA
Motus GI Holdings MOTS	6.58 M	-	-34.28 %	$ 263 K	Israel
Laboratory Corporation of America Holdings LH	2.23 B	$ 250.88	-0.87 %	$ 21 B	USA
Twist Bioscience Corporation TWST	247 M	$ 31.72	-1.34 %	$ 1.9 B	USA
ICON Public Limited Company ICLR	585 M	$ 182.22	-0.43 %	$ 15 B	Irlanda
IDEXX Laboratories IDXX	442 M	$ 676.53	-0.85 %	$ 55.8 B	USA
Lantheus Holdings LNTH	194 M	$ 66.55	-0.91 %	$ 4.61 B	USA